Impact Biomedical Inc. IBO
5.69
0.04
0.71%
as of 25 Sep
- Market cap
- $48.3M
- P/E
- 6.5×
Follow IBO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
6.60 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17,929.09 | 20,976.81 | 2,458.59 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
1,335.15 | (1,763.14) | 2,036.41 | (167.37) | |
P/B ratio |
44.78 | 55.61 | 12.96 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
18,156.55 | 21,180.69 | 2,555.76 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1,250.94) | (494.05) | (110.88) | (37.16) | |
EV/FCF |
(1,208.14) | (488.79) | (109.84) | (36.94) | |
Quick Ratio |
0.00 | 0.01 | 0.01 | 0.00 | |
Current Ratio |
0.16 | 0.22 | 0.35 | 0.04 | |
Net Debt/EBITDA |
0.02 | 0.01 | 0.00 | 0.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.67) | 0.20 | 0.02 | 0.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,533.33% | 657.14% | 1,571.43% | 288.89% | |
Selling, General and Administrative Expense of Revenue |
5,566.67% | 23,157.14% | 1,714.29% | 1,461.11% | |
Intangible Assets out of Total Assets |
0.98 | 0.98 | 0.98 | 0.95 | |
Share Based Compensation of Revenue |
0.00% | 20,571.43% | 114.29% | (1,050.00%) | |
Graham Net Nets |
0.00 | 0.00 | (0.01) | (0.25) | |
Graham Number |
1.61 | 0.00 | 0.00 | 8.05 | |
Earnings Yield |
15.16% | (3.84%) | (5.97%) | (46.79%) | |
Free Cash Flow Yield |
(0.08%) | (0.21%) | (0.95%) | (2.92%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.05) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.13 | 0.14 | 0.49 | (0.73) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.13 | 0.14 | 0.49 | (0.73) | |
Free Cash Flow |
0.47 | (0.46) | 0.10 | (0.61) | |
Working Capital |
(1.72) | (1.31) | (0.75) | (22.88) | |
Net Current Asset Value |
(2.41) | (2.00) | (1.44) | (26.14) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(23,300.00%) | (32,671.43%) | 74,928.57% | (8,166.67%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.07 | 0.07 | |
Average Payables |
0.51 | 0.49 | 0.33 | 0.79 | |
Average Inventory |
0.27 | 0.28 | — | — | |
Average Assets |
17.90 | 18.57 | 18.85 | 32.45 | |
Average Common Equity |
3.29 | 10.73 | 11.37 | 12.69 |
Columns are period end dates